PreludeDx™ to Present DCISionRT® and Novel Residual Risk Subtype Study Results During Scientific Oral Session at ASBrS 2022 Annual Meeting
"We remain committed to continuous innovation to enable physicians and patients to make personalized early-stage cancer treatment decisions and enhance patient outcomes."
- "We remain committed to continuous innovation to enable physicians and patients to make personalized early-stage cancer treatment decisions and enhance patient outcomes."
- DCISionRT is the only risk assessment test for patients with ductal carcinoma in situ (DCIS) that predicts radiation therapy benefit.
- DCISionRT's intelligent reporting provides a woman's recurrence risk after breast conserving surgery alone and with the addition of radiation therapy.
- PreludeDx is a leading personalized breast cancer diagnostics company dedicated to serving breast cancer patients and physicians worldwide.